Alclometasone

Alclometasone

Alclometasone Dipropionate

Published in Anton C. de Groot, Monographs in Contact Allergy, 2021

A 22-year-old woman noticed worsening of atopic dermatitis of the face when she started using alclometasone dipropionate 0.1% ointment. Patch tests were positive to the ointment (+) and to the corticosteroid 0.1% pet. (+ only at D4) but negative to the ointment base (5).

Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?

View Article

Journal Information

Published in Expert Opinion on Pharmacotherapy, 2020

Cecilia Bergonzini, Alessandro Leonetti, Marcello Tiseo, Elisa Giovannetti, Godefridus J. Peters

Indeed, in the phase I trial NCT00225121, grade 1 to 3 AEs were observed, including diarrhea (66.7%), rash (45%), fatigue (38%) and nausea (36%). In the ARCHER 1042 [29] phase II trial, the effect on dermatologic and gastrointestinal AE in NSCLC patients was investigated, by treating them with doxycycline against placebo in one cohort and with a probiotic plus topical aclometasone against placebo in the other. The results showed that doxycycline treatment significantly reduced the select dermatologic adverse events of interest (SDAEI) of grade ≥ 2 by 50% (P = 0.016) compared to the placebo. However, doxycycline was not able to reduce SDAEI of all grade in a statistically significant way. Aclometasone reduced SDAEI of all grades but not with statistical significance. Finally, the probiotic was ineffective in reducing gastrointestinal AEs.

Explore chapters and articles related to this topic

Alclometasone Dipropionate

Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?